Abstract
There is intense interest in the identification of novel biomarkers which improve the diagnosis of heart failure. Serum samples from 52 patients with systolic heart failure (EF < 40% plus signs and symptoms of failure) and 57 controls were analyzed by gas chromatography – time of flight – mass spectrometry and the raw data reduced to 272 statistically robust metabolite peaks. 38 peaks showed a significant difference between case and control (p < 5 × 10−5). Two such metabolites were pseudouridine, a modified nucleotide present in t- and rRNA and a marker of cell turnover, as well as the tricarboxylic acid cycle intermediate 2-oxoglutarate. Furthermore, 3 further new compounds were also excellent discriminators between patients and controls: 2-hydroxy, 2-methylpropanoic acid, erythritol and 2,4,6-trihydroxypyrimidine. Although renal disease may be associated with heart failure, and metabolites associated with renal disease and other markers were also elevated (e.g. urea, creatinine and uric acid), there was no correlation within the patient group between these metabolites and our heart failure biomarkers, indicating that these were indeed biomarkers of heart failure and not renal disease per se. These findings demonstrate the power of data-driven metabolomics approaches to identify such markers of disease.
Similar content being viewed by others
References
Amuro, Y., Nakaoka, H., Shimomura, S., Fujikura, M., Yamamoto, T., Tamura, S., Hada, T., Higashino, K. (1988) Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma. Clin. Chim. Acta, 178, 151–158
Anker, S.D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C.H., Cicoira, M., Shamim, W., Kemp, M., Segal, R., Osterziel, K.J., Leyva, F., Hetzer, R., Ponikowski, P., Coats, A.J. (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 107, 1991–1997
Bland, J.M., Altman, D.G. (1995) Multiple significance tests: the Bonferroni method. BMJ, 310, 170
Bongartz, L.G., Cramer, M.J., Doevendans, P.A., Joles, J.A., Braam, B. (2005) The severe cardiorenal syndrome: ‘Guyton revisited’. Eur. Heart. J., 26, 11–7
Broadhurst, D., Kell, D.B. (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics, 2, 171–196; DOI: 10.1007/s11306-006-0037-z
Bultitude, F.W., Newham, S.J. (1975) Identification of some abnormal metabolites in plasma from uremic subjects. Clin. Chem., 21, 1329–1334
Charette, M., Gray, M.W. (2000) Pseudouridine in RNA: what, where, how, and why. IUBMB Life, 49, 341–351
Csete, M., Doyle, J. (2004) Bow ties, metabolism and disease. Trends Biotechnol., 22, 446–450
Culleton, B.F., Larson, M.G., Evans, J.C., Wilson, P.W., Barrett, B.J., Parfrey, P.S., Levy, D. (1999a) Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch. Intern. Med. 159, 1785–1790
Culleton, B.F., Larson, M.G., Kannel, W.B., Levy, D. (1999b) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med., 131, 7–13
De Sousa, E., Veksler, V., Bigard, X., Mateo, P., Ventura-Clapier, R. (2000) Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation 102, 1847–1853
DiCiccio, T.J., Efron, B. (1996) Bootstrap confidence intervals. Stat. Sci., 11, 189–228
Drexler, H., Riede, U., Munzel, T., Konig, H., Funke, E., Just, H. (1992) Alterations of skeletal muscle in chronic heart failure. Circulation, 85, 1751–1759
Duarte, N.C., Becker, S.A., Jamshidi, N., Thiele, I., Mo, M.L., Vo, T.D., Srvivas, R., Palsson, B.Ø. (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. 104, 1777–1782
Dunn, W.B., Ellis, D.I. (2005) Metabolomics: current analytical platforms and methodologies. Trends Anal. Chem. 24, 285–294
Efron, B., Gong, G. (1983) A leisurely look at the bootstrap, the jackknife, and cross-validation. American Statistician 37, 36–48
Efron, B., Tibshirani, R.J. (1993) Introduction to the Bootstrap. London, Chapman and Hall
Finck, B.N., Kelly, D.P. (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116, 615–622
Harrigan G.G., Goodacre R. (Eds) (2003) Metabolic Profiling: its Role in Biomarker Discovery and Gene Function analysis. Boston, Kluwer Academic Publishers
Hierro, E., Ordonez, J., Bruna, J. M., Pin, C., Fernandez, M., de la Hoz, L. (2005) Volatile compound generation in dry fermented sausages by the surface inoculation of selected mould species. Eur. Food Res. Technol. 220, 494–501
Higley, B., De Mello, J., Jr., Oakes, D.J., Giles, G. R. (1982) Serum pseudouridine concentration as a marker of gastrointestinal cancer. Clin. Oncol. 8, 305–312
Hollander, M., Wolfe, D.A. (1973) Nonparametric Statistical Methods. New York, Wiley
Jauniaux, E., Hempstock, J., Teng, C., Battaglia, F. C., Burton, G.J. (2005) Polyol concentrations in the fluid compartments of the human conceptus during the first trimester of pregnancy: maintenance of redox potential in a low oxygen environment. J. Clin. Endocrinol. Metab. 90, 1171–1175
Kell, D.B. (2004) Metabolomics and systems biology: making sense of the soup. Curr. Op. Microbiol. 7, 296–307
Kell, D.B. (2006a) Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture FEBS J. 273, 873–894
Kell, D.B. (2006b) Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Disc. Today, 11, 1085–1092
Kell, D.B., Oliver, S.G. (2004) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26, 99–105
Kenny, L.C., Dunn, W.B., Ellis, D.I., Myers, J., Baker, P. N., The GOPEC Consortium and Kell, D.B. (2005) Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics. 1, 227–234 - online DOI: 10.1007/s11306–005-0003-1
Kirschenlohr, H.L., Griffin, J.L., Clarke, S.C., Rhydwen, R., Grace, A.A., Schofield, P.M., Brindle, K. M., Metcalfe, J. C. (2006) Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med., 12, 705–710
Leyva, F., Anker, S., Swan, J.W., Godsland, I.F., Wingrove, C.S., Chua, T.P., Stevenson, J.C., Coats, A.J. (1997) Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart. J. 18, 858–865
Leyva, F., Anker, S.D., Godsland, I.F., Teixeira, M., Hellewell, P.G., Kox, W.J., Poole-Wilson, P.A., Coats, A.J. (1998a) Uric acid in chronic heart failure: a marker of chronic inflammation. Eur. Heart. J. 19, 1814–1822
Leyva, F., Chua, T.P., Anker, S.D., Coats, A.J. (1998b) Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 47, 1156–1159
Mackay, D.J.C. (2003) Information Theory, Inference and Learning Algorithms. Cambridge: Cambridge University Press
Morgan, H.E., Gordon, E.E., Kira, Y., Chua, H.L., Russo, L.A., Peterson, C.J., McDermott, P.J., Watson, P. A. (1987) Biochemical mechanisms of cardiac hypertrophy. Annu. Rev. Physiol. 49, 533–543
Neijssel, O.M., Tempest, D.W. (1976) The role of energy-splitting reactions in the growth of Klebsiella aerogenes NCTC 418 in aerobic chemostat culture. Arch. Microbiol. 110, 305–311
Neubauer, S., Horn, M., Cramer, M., Harre, K., Newell, J. B., Peters, W., Pabst, T., Ertl, G., Hahn, D., Ingwall, J. S., Kochsiek, K. (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation, 96, 2190–2196
Nicholson, J.K., Holmes, E., Wilson, I.D. (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3, 431–438
Niwa, T., Takeda, N., Yoshizumi, H. (1998) RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note Kidney Int. 53, 1801–1806
O’Hagan, S., Dunn, W.B., Broadhurst, D., Williams, R., Ashworth, J.A., Cameron, M., Knowles, J., Kell, D. B. (2007) Closed-loop, multi-objective optimisation of two-dimensional gas chromatography (GCxGC-tof-MS) for serum metabolomics. Anal. Chem. 79, 464–476
O’Hagan, S., Dunn, W.B., Brown, M., Knowles, J.D., Kell, D.B. (2005) Closed-loop, multiobjective optimisation of analytical instrumentation: gas-chromatography-time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations. Anal. Chem. 77, 290–303
Ofengand, J. (2002) Ribosomal RNA pseudouridines and pseudouridine synthases. FEBS Lett. 514, 17–25
Oliver, S.G., Winson, M.K., Kell, D.B., Baganz, F. (1998) Systematic functional analysis of the yeast genome. Trends Biotechnol. 16, 373–378
Orešič, M., Vidal-Puig, A., Hänninen, V. (2006) Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev. Mol. Diagn. 6, 575–585
Pan, J.P., Liu, T.Y., Chiang, S.C., Lin, Y.K., Chou, C.Y., Chan, W.L., Lai, S.T. (2004) The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure. J. Chin. Med. Assoc. 67, 222–228
Pane, F., Savoia, M., Fortunato, G., Camera, A., Rotoli, B., Salvatore, F., Sacchetti, L. (1993) Serum pseudouridine in the diagnosis of acute leukaemias and as a novel prognostic indicator in acute lymphoblastic leukaemia. Clin. Biochem., 26, 513–520
Pearl, J. (2000) Causality: Models, Reasoning and Inference. Cambridge, Cambridge University Press
Perneger, T.V. (1998) What’s Wrong with Bonferroni Adjustments. Bmj, 316, 1236–1238
Pitkänen, E. (1972) Serum polyol pattern and urinary polyol excretion in diabetic and in uremic patients. Clin. Chim. Acta. 38, 221–230
Raamsdonk, L.M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M., Berden, J.A., Brindle, K.M., Kell, D.B., Rowland, J.J., Westerhoff, H.V., van Dam, K., Oliver, S.G. (2001) A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotechnol. 19, 45–50
Ransohoff, D.F. (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5, 142–149
Roboz, J., Kappatos, D., Holland, J.F. (1990) Polyol concentrations in serum during hemodialysis. Clin. Chem. 36, 2082–2086
Roboz, J., Kappatos, D.C., Greaves, J., Holland, J. F. (1984) Determination of polyols in serum by selected ion monitoring. Clin. Chem. 30, 1611–1615
Rothman, K.J., Greenland, S. (1998) Modern Epidemiology, 2nd ed. Philadelphia: Lippincott, Williams & Wilkins
Russo, T., Colonna, A., Salvatore, F., Cimino, F., Bridges, S., Gurgo, C. (1984) Serum pseudouridine as a biochemical marker in the development of AKR mouse lymphoma. Cancer Res. 44, 2567–2570
Sabatine, M.S., Liu, E., Morrow, D.A., Heller, E., McCarroll, R., Wiegand, R., Berriz, G.F., Roth, F.P., Gerszten, R.E. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868–3875
Sakai, H., Tsutamoto, T., Tsutsui, T., Tanaka, T., Ishikawa, C., Horie, M. (2006) Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ. J., 70, 1006–1011
Salvatore, F., Russo, T., Colonna, A., Cimino, L., Mazzacca, G., Cimino, F. (1983) Pseudouridine determination in blood serum as tumor marker. Cancer Detect. Prev. 6, 531–536
Schoots, A.C., Mikkers, F.E.P., Cramers, C.A.M.G., Ringoir, S. (1979) Profiling of uremic serum by high-resolution gas chromatography-electron-impact, chemical ionization mass spectrometry. J. Chromatogr. 164, 1–8
Smith, G.L., Shlipak, M.G., Havranek, E.P., Foody, J.M., Masoudi, F.A., Rathore, S.S., Krumholz, H.M. (2006) Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch. Intern. Med. 166, 1134–1142
Tamura, S., Fujioka, H., Nakano, T., Hada, T., Higashino, K. (1987) Serum pseudouridine as a biochemical marker in small cell lung cancer. Cancer. Res. 47, 6138–6141
Troughton, R.W., Frampton, C.M., Yandle, T.G., Espiner, E.A., Nicholls, M.G., Richards, A.M. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 355, 1126–1130
Tsutamoto, T., Wada, A., Sakai, H., Ishikawa, C., Tanaka, T., Hayashi, M., Fujii, M., Yamamoto, T., Dohke, T., Ohnishi, M., Takashima, H., Kinoshita, M., Horie, M. (2006) Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J. Am. Coll. Cardiol. 47, 582–586
Underwood, B.R., Broadhurst, D., Dunn, W.B., Ellis, D.I., Michell, A.W., Vacher, C., Mosedale, D.B., Kell, D.B., Barker, R., Grainger, D.J., Rubinsztein, D. C. (2006) Huntington’s disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain, 29, 877–886
van der Greef, J., Hankemeier, T., McBurney, R.N. (2006) Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics, 7, 1087–1094
van der Greef, J., Stroobant, P., van der Heijden, R. (2004) The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol., 8, 559–565
Verhoeven, N.M., Huck, J.H., Roos, B., Struys, E. A., Salomons, G.S., Douwes, A.C., van der Knaap, M. S., Jakobs, C. (2001) Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am. J. Hum. Genet. 68, 1086–1092
Wacholder, S., Chanock, S., Garcia-Closas, M., El Ghormli, L., Rothman, N. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer. Inst. 96, 434–442
Wamelink, M.M., Smith, D.E., Jakobs, C., Verhoeven, N.M. (2005) Analysis of polyols in urine by liquid chromatography-tandem mass spectrometry: A useful tool for recognition of inborn errors affecting polyol metabolism. J. Inherit. Metab. Dis. 28, 951–963
Xu, G., Schmid, H.R., Lu, X., Liebich, H.M., & Lu, P. (2000) Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed Chromatogr, 14, 459–63
Zaphiriou, A., Robb, S., Murray-Thomas, T., Mendez, G., Fox, K., McDonagh, T., Hardman, S.M., Dargie, H.J., Cowie, M.R. (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur. J. Heart Fail. 7, 537–541
Zheng, Y.F., Kong, H.W., Xiong, J.H., Lv, S., Xu, G.W. (2005) Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin Biochem, 8, 24–30
Acknowledgments
DBK thanks the BBSRC, EPSRC, RSC and BHF and LN thanks the MRC and the BHF for financial support. We thank the referees for some very thoughtful and helpful comments. DBK thanks Prof Phil Baker for a useful discussion. This is a contribution from the Manchester Centre for Integrative Systems Biology (www.mcisb.org).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Warwick B. Dunn, David I. Broadhurst and Sasalu M. Deepak contributed equally to this work.
Rights and permissions
About this article
Cite this article
Dunn, W.B., Broadhurst, D.I., Deepak, S.M. et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 3, 413–426 (2007). https://doi.org/10.1007/s11306-007-0063-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11306-007-0063-5